Genetic Risk Score Is Associated With Prevalence of Advanced Neoplasms in a Colorectal Cancer Screening Population.

Authors:
Hauke Thomsen, Dr.
Hauke Thomsen, Dr.
GeneWerk GmbH
Senior Bioinformatician
Bioinformatics, Biostatistics, Genetics
Heidelberg, Baden-W├╝rttemberg/Germany | Germany
Yesilda Balavarca
Yesilda Balavarca
Medical University of Vienna
Austria
Jacklyn N Hellwege
Jacklyn N Hellwege
Wake Forest School of Medicine
United States
Martha J Shrubsole
Martha J Shrubsole
Vanderbilt Epidemiology Center
Nashville | United States
Hermann Brenner
Hermann Brenner
German Cancer Research Center (DKFZ)
Germany

Gastroenterology 2018 07 21;155(1):88-98.e10. Epub 2018 Mar 21.

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany; Division of Preventive Oncology, German Cancer Research Center and National Center of Tumor Diseases, Heidelberg, Germany. Electronic address:

Background & Aims: The presence of specific single nucleotide polymorphisms (SNPs) can be used to calculate an individual's risk for colorectal cancer (CRC), called a genetic risk score (GRS). We investigated whether GRS can identify individuals with clinically relevant neoplasms in a screening colonoscopy population.

Methods: We derived a GRS based on 48 SNPs associated with CRC, identified in a comprehensive literature search. We obtained genetic data from 1043 participants (50-79 years old) in a screening colonoscopy study in Germany, recruited from 2005 through 2013 (294 with advanced neoplasms, 249 with non-advanced adenoma (NAAs), and 500 without neoplasms). Each participant was assigned a GRS by aggregating their risk alleles (0, 1, or 2). Risk of advanced neoplasms and NAA according to GRS was calculated by multiple logistic regression. Risk advancement periods were calculated. We replicated our findings using data from a subset of the Tennessee Colorectal Polyp Study.

Results: An increased GRS was associated with higher prevalence of advanced neoplasms, but not NAAs. Participants in the middle and upper tertiles of GRS had a 2.2-fold and 2.7-fold increase in risk, respectively, of advanced neoplasms compared to those in the lower tertile. Adjusted odds ratios (ORs) were 1.09 (95% confidence interval [CI], 0.76-1.57) for NAA in the middle tertile and 1.05 (95% CI, 0.70-1.55) for NAA in the upper tertile. The ORs were largest for proximal advanced neoplasms for participants in the middle tertile (OR, 3.55; 95% CI 1.85-6.82) and the upper tertile (OR, 3.61; 95% CI 1.84-7.10). The risk advancement period for medium vs low GRS was 13.4 years (95% CI 4.8-22.0) and for high vs low GRS was 17.5 years (95% CI, 7.8-27.3).

Conclusions: In a genetic analysis of participants in a CRC screening study in Germany, an increased GRS (based on CRC-associated SNPs) was associated with increased prevalence of advanced neoplasms. These findings might be used in defining risk-adapted screening ages.

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2018.03.030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035076PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
July 2018
11 Reads
16.720 Impact Factor

Publication Analysis

Top Keywords

advanced neoplasms
28
prevalence advanced
12
grs
10
neoplasms
9
upper tertile
8
low grs
8
screening colonoscopy
8
grs based
8
risk advancement
8
risk advanced
8
study germany
8
increased grs
8
snps associated
8
participants middle
8
years 95%
8
middle tertile
8
colorectal cancer
8
genetic risk
8
risk score
8
risk
7

Similar Publications